American Journal of Ophthalmology
Volume 142, Issue 5 , Pages 721-725.e1 , November 2006

Acute Endophthalmitis in Eyes Treated Prophylactically with Gatifloxacin and Moxifloxacin

  • Vincent A. Deramo, MD

      Affiliations

    • Department of Ophthalmology, North Shore–Long Island Jewish Health System, Albert Einstein College of Medicine, New Hyde Park, New York
    • Long Island Vitreoretinal Consultants, Great Neck, New York.
    • Corresponding Author InformationInquiries to Vincent A. Deramo, MD, 600 Northern Blvd., #216, Great Neck, NY 11021
    • ,
  • James C. Lai, MD

      Affiliations

    • Department of Ophthalmology, North Shore–Long Island Jewish Health System, Albert Einstein College of Medicine, New Hyde Park, New York
    • Long Island Vitreoretinal Consultants, Great Neck, New York.
    • ,
  • David M. Fastenberg, MD

      Affiliations

    • Department of Ophthalmology, North Shore–Long Island Jewish Health System, Albert Einstein College of Medicine, New Hyde Park, New York
    • Long Island Vitreoretinal Consultants, Great Neck, New York.
    • ,
  • Ira J. Udell, MD

      Affiliations

    • Department of Ophthalmology, North Shore–Long Island Jewish Health System, Albert Einstein College of Medicine, New Hyde Park, New York

,Accepted 25 May 2006.

References 

  1. Taban M, Behrens A, Newcomb RL, et al. Acute endophthalmitis following cataract surgery: a systematic review of the literature. Arch Ophthalmol. 2005;123:613–620
  2. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463–466
  3. Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136:500–505
  4. Kunimoto DY, Sharma S, Garg P, Rao GN. In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin (Emerging resistance). Ophthalmology. 1999;106:80–85
  5. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a five-year review. Ophthalmology. 1999;106:1313–1318
  6. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000;107:1497–1502
  7. Kowalski RP, Pandya AN, Karenchak LM, et al. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa. Ophthalmology. 2001;108:1826–1829
  8. Marangon FB, Miller D, Muallem MS, et al. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am J Ophthalmol. 2004;137:453–458
  9. Kotlus BS, Wymbs RA, Vellozzi EM, Udell IJ. In vitro activity of fluoroquinolones, vancomycin, and gentamicin against methicillin-resistant Staphylococcus aureus (MRSA) ocular isolates. Am J Ophthalmol. 2006;142:726–729
  10. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study (A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis). Arch Ophthalmol. 1995;113:1479–1496
  11. Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update. Ophthalmology. 2002;109:13–24
  12. Kowalski RP, Romanowski EG, Mah FS, et al. Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model. Am J Ophthalmol. 2004;138:33–37
  13. Moshirfar M, Marx DP, Mirzaian G. Endophthalmitis in patients using fourth-generation fluoroquinolones following phacoemulsification. J Cataract Refract Surg. 2005;31:1669–1670
  14. Miller D, Flynn PM, Scott IU, et al. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch Ophthalmol. 2006;124:479–483
  15. Blondeau JM. Fluoroquinolones: mechanisms of action, classification, and development of resistance. Surv Ophthalmol. 2004;49:S73–S78
  16. Hariprasad SM, Blinder KJ, Shah GK, et al. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol. 2005;123:39–44
  17. Solomon R, Donnenfeld ED, Perry HD, et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology. 2005;112:466–469

PII: S0002-9394(06)00701-X

doi: 10.1016/j.ajo.2006.05.044

American Journal of Ophthalmology
Volume 142, Issue 5 , Pages 721-725.e1 , November 2006

Article Tools

* Image Usage & Resolution